By Karen Roman
SkylineDx said it can predict metastases and outperform existing staging systems for the country’s second most common type of skin cancer, Cutaneous Squamous Cell Carcinoma (CSCC).
The results will be presented at the 22nd European Association of Dermato-Oncology Congress, held on April 23-25, 2026, in Prague and online.
“This marks our first oral presentation at a conference on our CSCC signature, representing our progress toward more accurate risk stratification for this high incidence disease,” said Dharminder Chahal, SkylineDx CEO.
READ MORE
Final Agenda and Registration – 2nd Princeton CorpGov Forum: Endowments, Activism and Entertainment
Never Miss our Weekly Highlights HERE
